TLDR:
- Bluejay Therapeutics, a company focused on developing novel therapeutics, raised $182M in Series C funding.
- The funding will be used to accelerate the clinical development of BJT-778 for chronic hepatitis D (HDV) and other promising candidates in Bluejay’s pipeline for the treatment of chronic hepatitis B.
Bluejay Therapeutics, based in San Mateo, CA, secured $182M in Series C financing led by Frazier Life Sciences. The funding round also saw participation from a range of new and existing investors, including RA Capital Management, T. Rowe Price, Wellington Management, Novo Holdings, RiverVest Venture Partners, Octagon Capital, Arkin Bio Ventures, HBM Healthcare Investments, and Unicorn Capital.
Following the funding, Bluejay added Daniel Estes, a General Partner at Frazier, to its Board of Directors. The company plans to use the funds to advance the clinical development of BJT-778, a treatment for chronic hepatitis D (HDV), and to support the progression of other promising candidates in their pipeline for chronic hepatitis B.
Bluejay Therapeutics, led by CEO Dr. Keting Chu, is focused on developing treatments for viral and liver diseases. Their lead program, BJT-778, is a fully human IgG1 monoclonal antibody designed to provide anti-HBV and anti-HDV benefits by neutralizing and clearing HBV and HDV virions as well as depleting HBsAg-containing subviral particles. The company is also working on other innovative programs for chronic HBV, including a TLR9 agonist (Cavrotolimod) and a liver targeted transcript inhibitor (BJT-628) with the goal of achieving higher rates of functional cure.
